India Glycols Q3FY26 Results: Profit Up 18.8% YoY to ₹67.57 Crore
India Glycols reported a consolidated profit after tax of ₹67.57 crore for Q3FY26, up 18.8% YoY. Nine-month profit stood at ₹205.88 crore, up 23.4% YoY. Revenue for Q3FY26 was ₹2,551.10 crore. The Board approved the results on February 10, 2026.
The results show a healthy increase in profitability, which is generally positive for investors. However, the revenue growth is modest, and the ongoing corporate restructuring may introduce some uncertainty.
The company reported a year-on-year increase in profit for both the quarter and the nine-month period, indicating positive financial performance.
India Glycols Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025. The company reported a consolidated profit after tax of ₹67.57 crore for the quarter, an increase of 18.8% compared to ₹56.81 crore in the same period last year. Revenue from operations for the quarter stood at ₹2,551.10 crore, a marginal increase from ₹2,424.01 crore in the corresponding quarter of the previous year.
For the nine-month period ended December 31, 2025, the consolidated profit after tax was ₹205.88 crore, up from ₹166.90 crore in the previous year. Revenue from operations for the nine months reached ₹7,466.62 crore, compared to ₹6,850.30 crore in the same period last year.
The Board of Directors met on February 10, 2026, to approve these results. The company also mentioned the ongoing Scheme of Arrangement involving the demerger of its Bio Pharma undertaking and the Spirits & Biofuel Undertaking, with an appointed date of April 1, 2026. Additionally, the company had previously approved a stock split of its shares and a preferential allotment of equity shares, which have since been completed and listed.
What to do with a filing like this
India Glycols Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by India Glycols Limited. Read the original for the full detail.